A Phase 1 interventional study of Palbociclib and Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by Pfizer. Completed at 26 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-06.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 1, open label, multi center, multiple dose, dose escalation, safety, pharmacokinetic and pharmacodynamic study of palbociclib in combination with nab-P, in sequential cohorts of adult patients with mPDAC, with MTD expansion cohort(s). Approximately 30-60 patients are expected to be enrolled in the overall study.
The study has 2 parts:
All patients (in Part A and B) will receive nab-P intravenously once weekly for 3 weeks out of each 28-day cycle. Palbociclib oral dosing will be once daily on Days 1-21 of each 28-day cycle. To allow for PK evaluation of nab-P administered alone, nab-P will be administered on Day -2 for Cycle 1 only. Subsequent cycles will administer both nab-P and palbociclib on Day 1. Alternate dosing schedules for palbociclib may be explored based on emerging PK, PD, and safety data.
Patients will be treated as long as they are clinically benefiting from investigational product without unacceptable toxicity, objective disease progression, or withdrawal of consent. A modified visit schedule will be implemented for patients who are on investigational product for more than 2 years.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle. Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
Drug: Palbociclib · Drug: Nab-Paclitaxel
Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle.
Also known as: Ibrance
Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
Also known as: Abraxane
Number of Participants With Dose Limiting Toxicities
Adverse events (AEs) considered as dose limiting toxicities (DLTs) included: hematologic: Grade 4 neutropenia lasting \>4 days; Febrile neutropenia (defined as neutropenia Grade\>=3 \[absolute neutrophil count {ANC}\<1000 cells/cubic millimeter {mm\^3}\] and a body temperature \>=38.5 \[degrees centigrade\]℃) requiring antibiotic or antifungal treatment; any Grade 4 thrombocytopenia (\<25000/mm\^3 or 25.0\*10\^9/\[liter\]L). Non-hematologic: Grade \>=3 toxicities, except those that had not been maximally treated (eg, nausea, vomiting, diarrhea). Any AE that caused a palbociclib treatment interruption of greater than 7 consecutive days or caused any combination of interruption/reduction for \>=14 days. Any AE that caused omission or reduction of at least 2 of the 3 weekly doses of nab-P.
Time frame: From Day 1 until pre-dose Cycle 2 Day 1
Number of Participants With Adverse Events
An AE was any untoward medical occurrence in a clinical investigation patient administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. An serious AE (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of investigational product. Disease progression was not considered a treatment emergent AE unless the participant died of disease prior to 28 days after discontinuation of treatment. Treatment emergent AEs with cause possibly, probably or definitely related to treatment, as judged by the investigator, were defined as treatment-related AEs. AEs were graded by investigator according to CTCAE v4.03.
Time frame: From the signing of informed consent up to 56 days after the last administration of the investigational product, or 365 days from the first dose of investigational product, whichever is later
Number of Participants With Laboratory Abnormalities
The number of participants with following laboratory abnormalities meeting any of the Grades 1 to 4 classified according to NCI CTCAE v4.0 were summarized: hematology (anemia, hemoglobin increased, lymphocyte count increased, lymphopenia, neutrophils, platelets and white blood cells) and chemistry laboratory tests (alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, bilirubin, creatinine, hypercalcemia, hyperglocemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia, lipase).
Time frame: From screening to the end of treatment/withdrawal visit (up to 63 days from last dose of investigational product).
Number of Participants With Vital Signs Data Meeting Pre-specified Criteria
Vital signs evaluation included sitting diastolic blood pressure (DBP), systolic blood pressure (SBP), and pulse rate. Suggest text: Vital signs categorical summary included: 1)SBP\>150mmHg or DBP\>100mmHg; 2)SBP\>200mmHg or DBP\>110mmHg; 3)SBP increase \>=20 and \<40mmHg; 4)SBP increase \>=40 and \<60mmHg; 5)SBP increase\>=60mmHg; 6)DBP increase \>=10 and \<20mmHg; 7)DBP increase \>=20 and \<30mmHg; 8)DBP increase \>=30mmHg; 9)pulse rate\>120bpm; 10)pulse rate\<50bpm.
Time frame: From screening to the end of treatment/withdrawal visit (up to 63 days from last dose of investigational product).
Number of Participants With 20% Maximum Reduction From Baseline in Ca19-9
Carbohydrate antigen 19-9 (Ca19-9) is a clinical pharmacodynamic (PD) marker associated with metastatic pancreatic ductal adenocarcinoma (mPDAC).
Time frame: From screening to the end of treatment/withdrawal visit (up to 63 days from last dose of investigational product).
Number of Participants With 50% Maximum Reduction From Baseline in Ca19-9
Ca19-9 is a clinical PD marker associated with metastatic mPDAC.
Time frame: From screening to the end of treatment/withdrawal visit (up to 63 days from last dose of investigational product).
Number of Participants With 70% Maximum Reduction From Baseline in Ca19-9
Ca19-9 is a clinical PD marker associated with metastatic mPDAC.
Time frame: From screening to the end of treatment/withdrawal visit (up to 63 days from last dose of investigational product).
Number of Participants With 90% Maximum Reduction From Baseline in Ca19-9
Ca19-9 is a clinical PD marker associated with metastatic mPDAC.
Time frame: From screening to the end of treatment/withdrawal visit (up to 63 days from last dose of investigational product).
Objective Response Rate
Percentage of participants who achieved objective response (OR) based on investigator assessment is presented. OR is defined as a complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Objective response rate (ORR) was defined as the percentage of participants with a best overall response of CR or PR relative to all anti-tumor evaluable participants.
Time frame: From screening to 365 days from the last dose of investigational product
Duration of Response
The duration of response was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression or to death due to any cause, whichever occurred first. Disease progression was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm.
Time frame: From screening to 365 days from the last dose of investigational product
Progression Free Survival
The progression free survival (PFS) was defined as the time from the date of first dose to the date of the first documentation of objective tumor progression as per RECIST v1.1 or death due to any cause in the absence of documented progression disease, whichever occurred first.
Time frame: From screening to 365 days from the last dose of investigational product
Six-month Progression-free Survival Rate (6m-PFSR)
6m-PFS was defined as PFS status (progression free and alive, or not) at Month 6. It was summarized as a product limit estimator based on the Kaplan-Meier method to account for censored events.
Time frame: From screening to 6 months after first dose of investigational product
Overall Survival (OS)
OS was defined as the time from the date of first dose to the date of death due to any cause. Following the end of treatment visit, survival status was collected in all participants every month until 12 months (365 days) had elapsed from the last dose of investigational product.
Time frame: From screening to 365 days from the last dose of investigational product
Number of Participants With Positive p16
p16 is a tumor suppressor protein which plays an important role in cell cycle regulation. The analysis of biomarker p16 expression might aid in the identification of patient subpopulations most likely to benefit from treatment. The results from p16 expression testing by immunohistochemistry (IHC) was used for sensitivity analyses. (a) and (b) :p16 cutoff utilizing the optimal cut point identified by the ORC analysis for the OS (a) or PFS (b) and the p16 positive tumor cells.
Time frame: From Day-2 to up to 63 days from last dose of investigational product
Retinoblastoma Protein (Rb) Percent Positive Cell (Nuclear Staining)
Rb is a tumor suppressor protein that is dysfunctional in several major cancers. The results from Rb expression testing by IHC was used for sensitivity analyses.
Time frame: From Day-2 to up to 63 days from last dose of investigational product
Rb H-score Nuclear Staining
Rb is a tumor suppressor protein that is dysfunctional in several major cancers. The results from Rb expression testing by IHC was used for sensitivity analyses. The H-score is a method of assessing the extent of nuclear immunoreactivity, applicable to steroid receptors. The score is obtained by the formula: 3\*percentage of strongly staining nuclei + 2\*percentage of moderately staining nuclei + percentage of weakly staining nuclei, giving the range of 0 to 300
Time frame: From Day-2 to up to 63 days from last dose of investigational product
Palbociclib Multiple Dose Maximum Plasma Concentration (Cmax)
The palbociclib multiple dose maximum plasma concentration(Cmax) was observed directly from data.
Time frame: Cycle 1 Day 13 at 0 (pre-dose), 2, 4, 6, 8 and 24 hours post palbociclib dose, and pre-dose on Cycle 2, Days 1 and 15.
Palbociclib Multiple Dose Time for Cmax (Tmax)
The palbociclib multiple dose time for Cmax (Tmax) was observed directly from data.
Time frame: Cycle 1 Day 13 at 0 (pre-dose), 2, 4, 6, 8 and 24 hours post palbociclib dose, and pre-dose on Cycle 2, Days 1 and 15.
Palbociclib Area Under the Plasma Concentration-time Curve for Dosing Interval τ (AUCτ)
The palbociclib area under the plasma concentration-time curve for dosing interval τ (AUCτ) was observed directly from data.
Time frame: Cycle 1 Day 13 at 0 (pre-dose), 2, 4, 6, 8 and 24 hours post palbociclib dose, and pre-dose on Cycle 2, Days 1 and 15.
Palbociclib Multiple Dose Trough Plasma Concentration(Ctrough)
The palbociclib multiple dose trough plasma concentration (Ctrough) was observed directly from data.
Time frame: Cycle 1 Day 13 at 0 (pre-dose), 2, 4, 6, 8 and 24 hours post palbociclib dose, and pre-dose on Cycle 2, Days 1 and 15.
Palbociclib Multiple Dose Apparent Clearance (CL/F)
The palbociclib multiple dose apparent clearance (CL/F) was observed directly from data.
Time frame: Cycle 1 Day 13 at 0 (pre-dose), 2, 4, 6, 8 and 24 hours post palbociclib dose, and pre-dose on Cycle 2, Days 1 and 15.
Nab-P Cmax
The nab-P Cmax on Cycle 1 Day -1 and Day 13 were observed directly from data.
Time frame: Prior to nab-P infusion and at 30 min (end of infusion), 1, 2, 4, 6, 8, 24, and 48 hours post the start of paclitaxel infusion on Day -2 and 13 of Cycle 1.
Nab-P Tmax
The nab-P Tmax on Day -1 and Day 13 were observed directly from data.
Time frame: Prior to nab-P infusion and at 30 min (end of infusion), 1, 2, 4, 6, 8, 24, and 48 hours post the start of paclitaxel infusion on Day -2 and 13 of Cycle 1.
Nab-P Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration (AUClast)
The nab-P area under the plasma concentration-time curve from time 0 to last quantifiable concentration (AUClast) on Day -1 and Day 13 were observed directly from data.
Time frame: Prior to nab-P infusion and at 30 min (end of infusion), 1, 2, 4, 6, 8, 24, and 48 hours post the start of paclitaxel infusion on Day -2 and 13 of Cycle 1.
Nab-P Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinite Time (AUCinf)
The nab-P area under the plasma concentration-time curve from time 0 extrapolated to infinite time (AUCinf) on Day -1 and Day 13 observed directly from data.
Time frame: Prior to nab-P infusion and at 30 min (end of infusion), 1, 2, 4, 6, 8, 24, and 48 hours post the start of paclitaxel infusion on Day -2 and 13 of Cycle 1.
Nab-P Terminal Plasma Elimination Half-life (t1/2)
The nab-P t1/2 on Day -1 and Day 13 were observed directly from data.
Time frame: Prior to nab-P infusion and at 30 min (end of infusion), 1, 2, 4, 6, 8, 24, and 48 hours post the start of paclitaxel infusion on Day -2 and 13 of Cycle 1.
Nab-P Clearance (CL)
The nab-P clearance on Day -1 and Day 13 were observed directly from data.
Time frame: Prior to nab-P infusion and at 30 min (end of infusion), 1, 2, 4, 6, 8, 24, and 48 hours post the start of paclitaxel infusion on Day -2 and 13 of Cycle 1.
Nab-P Volume of Distribution (Vz)
The nab-P on Day -1 and Day 13 were observed directly from data.
Time frame: Prior to nab-P infusion and at 30 min (end of infusion), 1, 2, 4, 6, 8, 24, and 48 hours post the start of paclitaxel infusion on Day -2 and 13 of Cycle 1.
| Milestone | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100mg/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100 mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 |
|---|---|---|---|---|---|---|---|---|
| Started | 3 | 7 | 4 | 11 | 11 | 11 | 9 | 20 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 7 | 4 | 11 | 11 | 11 | 9 | 20 |
| Withdrew: Subject refused further follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 3 | 0 | 1 | 1 | 0 | 2 | 4 |
| Withdrew: Death | 3 | 4 | 4 | 10 | 10 | 11 | 7 | 15 |
Adverse events (AEs) considered as dose limiting toxicities (DLTs) included: hematologic: Grade 4 neutropenia lasting \>4 days; Febrile neutropenia (defined as neutropenia Grade\>=3 \[absolute neutrophil count {ANC}\<1000 cells/cubic millimeter {mm\^3}\] and a body temperature \>=38.5 \[degrees centigrade\]℃) requiring antibiotic or antifungal treatment; any Grade 4 thrombocytopenia (\<25000/mm\^3 or 25.0\*10\^9/\[liter\]L). Non-hematologic: Grade \>=3 toxicities, except those that had not been maximally treated (eg, nausea, vomiting, diarrhea). Any AE that caused a palbociclib treatment interruption of greater than 7 consecutive days or caused any combination of interruption/reduction for \>=14 days. Any AE that caused omission or reduction of at least 2 of the 3 weekly doses of nab-P.
| Participants | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 |
|---|---|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities | 0 | 1 | 0 | 0 | 1 | 1 | 1 |
An AE was any untoward medical occurrence in a clinical investigation patient administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. An serious AE (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of investigational product. Disease progression was not considered a treatment emergent AE unless the participant died of disease prior to 28 days after discontinuation of treatment. Treatment emergent AEs with cause possibly, probably or definitely related to treatment, as judged by the investigator, were defined as treatment-related AEs. AEs were graded by investigator according to CTCAE v4.03.
| Participants | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MTD+DL3B |
|---|---|---|---|---|---|---|---|---|---|
| All causality treatment-emergent AEs | 3 | 7 | 4 | 11 | 11 | 11 | 9 | 20 | 27 |
| Treatment-related treatment-emergent AEs | 3 | 7 | 4 | 10 | 11 | 11 | 9 | 20 | 27 |
| All causality SAEs | 2 | 4 | 3 | 4 | 6 | 9 | 2 | 12 | 15 |
| Treatment-related SAES | 0 | 0 | 1 | 0 | 2 | 4 | 1 | 6 | 6 |
| All causality Grade 3 or 4 AEs | 3 | 6 | 3 | 9 | 11 | 10 | 5 | 20 | 27 |
| Treatment-related Grade 3 or 4 AEs | 2 | 5 | 2 | 8 | 11 | 7 | 4 | 20 | 27 |
| All causality Grade 5 AEs | 0 | 1 | 1 | 1 | 3 | 5 | 0 | 1 | 2 |
| Treatment-related Grade 5 AEs | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
The number of participants with following laboratory abnormalities meeting any of the Grades 1 to 4 classified according to NCI CTCAE v4.0 were summarized: hematology (anemia, hemoglobin increased, lymphocyte count increased, lymphopenia, neutrophils, platelets and white blood cells) and chemistry laboratory tests (alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, bilirubin, creatinine, hypercalcemia, hyperglocemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia, lipase).
| Participants | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MTD+DL3B |
|---|---|---|---|---|---|---|---|---|---|
| Anemia | 3 | 7 | 4 | 11 | 11 | 11 | 8 | 20 | 27 |
| Hemoglobin increased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Lymphocyte count increased | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Lymphopenia | 3 | 7 | 2 | 9 | 10 | 11 | 7 | 20 | 27 |
| Neutrophils (absolute) | 3 | 7 | 2 | 10 | 10 | 9 | 8 | 20 | 27 |
| Platelets | 2 | 4 | 0 | 8 | 8 | 5 | 1 | 10 | 15 |
| White blood cells | 3 | 7 | 3 | 10 | 10 | 9 | 8 | 20 | 27 |
| Alanine aminotransferase (ALT) | 2 | 4 | 1 | 3 | 4 | 4 | 5 | 11 | 15 |
| Alkaline phosphatase | 2 | 6 | 3 | 9 | 8 | 8 | 6 | 15 | 20 |
| Amylase | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 2 |
| Aspartate aminotransferase (AST) | 2 | 3 | 1 | 5 | 6 | 5 | 6 | 8 | 13 |
| Bilirubin (total) | 0 | 2 | 0 | 1 | 0 | 2 | 0 | 4 | 4 |
| Creatinine | 3 | 7 | 3 | 10 | 11 | 10 | 9 | 18 | 25 |
| Hypercalcemia | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 2 |
| Hyperglycemia | 3 | 7 | 3 | 9 | 7 | 10 | 7 | 16 | 23 |
| Hyperkalemia | 0 | 0 | 2 | 1 | 4 | 2 | 3 | 6 | 9 |
| Hypermagnesemia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Hypernatremia | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 2 | 2 |
| Hypoalbuminemia | 2 | 2 | 3 | 5 | 5 | 7 | 4 | 10 | 13 |
| Hypocalcemia | 2 | 2 | 2 | 5 | 5 | 5 | 5 | 9 | 12 |
| Hypoglycemia | 1 | 1 | 1 | 1 | 3 | 0 | 0 | 3 | 6 |
| Hypokalemia | 2 | 2 | 0 | 0 | 1 | 1 | 0 | 5 | 6 |
| Hypomagnesemia | 1 | 0 | 2 | 1 | 3 | 1 | 0 | 3 | 6 |
| Hyponatremia | 3 | 2 | 3 | 6 | 3 | 3 | 2 | 6 | 8 |
| Hypophosphatemia | 0 | 1 | 1 | 4 | 0 | 3 | 2 | 6 | 6 |
| Liapase | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 5 | 6 |
Vital signs evaluation included sitting diastolic blood pressure (DBP), systolic blood pressure (SBP), and pulse rate. Suggest text: Vital signs categorical summary included: 1)SBP\>150mmHg or DBP\>100mmHg; 2)SBP\>200mmHg or DBP\>110mmHg; 3)SBP increase \>=20 and \<40mmHg; 4)SBP increase \>=40 and \<60mmHg; 5)SBP increase\>=60mmHg; 6)DBP increase \>=10 and \<20mmHg; 7)DBP increase \>=20 and \<30mmHg; 8)DBP increase \>=30mmHg; 9)pulse rate\>120bpm; 10)pulse rate\<50bpm.
| Participants | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MTD+DL3B |
|---|---|---|---|---|---|---|---|---|---|
| Maximum on-study SBP>150 or DBP>100 | 1 | 1 | 0 | 2 | 2 | 2 | 1 | 4 | 5 |
| Maximum on-study SBP >200 or DBP>110 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Maximum increase from Baseline SBP>=20 and SBP<40 | 0 | 0 | 0 | 5 | 0 | 2 | 1 | 4 | 4 |
| Maximum increase from Baseline SBP>=40 and SBP<60 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 1 | 3 |
| Maximum increase from Baseline SBP>=60 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Maximum increase from Baseline DBP>=10 and DPB<20 | 0 | 0 | 1 | 3 | 5 | 1 | 4 | 6 | 9 |
| Maximum increase from Baseline DBP>= 20 and DBP<30 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Maximum increase from Baseline DBP >=30 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| Maximum on-study pulse rate (bpm) >120 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Maximum on-study pulse rate (bpm) <50 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Carbohydrate antigen 19-9 (Ca19-9) is a clinical pharmacodynamic (PD) marker associated with metastatic pancreatic ductal adenocarcinoma (mPDAC).
| Participants | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MTD+DL3B |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With 20% Maximum Reduction From Baseline in Ca19-9 | 3 | 5 | 0 | 7 | 6 | 5 | 3 | 10 | 15 |
Ca19-9 is a clinical PD marker associated with metastatic mPDAC.
| Participants | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MTD+DL3B |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With 50% Maximum Reduction From Baseline in Ca19-9 | 1 | 4 | 0 | 5 | 6 | 4 | 2 | 5 | 10 |
Ca19-9 is a clinical PD marker associated with metastatic mPDAC.
| Participants | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MTD+DL3B |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With 70% Maximum Reduction From Baseline in Ca19-9 | 0 | 1 | 0 | 3 | 4 | 1 | 1 | 4 | 8 |
Ca19-9 is a clinical PD marker associated with metastatic mPDAC.
| Participants | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MTD+DL3B |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With 90% Maximum Reduction From Baseline in Ca19-9 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 |
Percentage of participants who achieved objective response (OR) based on investigator assessment is presented. OR is defined as a complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Objective response rate (ORR) was defined as the percentage of participants with a best overall response of CR or PR relative to all anti-tumor evaluable participants.
| Percentage of participants | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MTD+DL3B |
|---|---|---|---|---|---|---|---|---|---|
| Objective Response Rate | — | — | — | — | 28.6 (3.7 to 71.0) | — | — | 6.3 (0.2 to 30.2) | 13.0 (2.8 to 33.6) |
The duration of response was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression or to death due to any cause, whichever occurred first. Disease progression was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm.
| Months | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MTD+DL3B |
|---|---|---|---|---|---|---|---|---|---|
| Duration of Response | — | — | — | — | NA (3.8 to NA) | — | — | 7.4 (NA to NA) | 7.4 (3.8 to NA) |
The progression free survival (PFS) was defined as the time from the date of first dose to the date of the first documentation of objective tumor progression as per RECIST v1.1 or death due to any cause in the absence of documented progression disease, whichever occurred first.
| Months | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MTD+DL3B |
|---|---|---|---|---|---|---|---|---|---|
| Progression Free Survival | 9.1 (3.7 to 9.1) | 9.5 (1.8 to NA) | 1.7 (1.4 to 1.9) | 3.5 (1.7 to 7.2) | 5.5 (0.8 to 14.5) | 5.3 (1.6 to 6.9) | 1.8 (1.5 to 8.6) | 3.8 (2.4 to 9.7) | 5.3 (3.5 to 9.7) |
6m-PFS was defined as PFS status (progression free and alive, or not) at Month 6. It was summarized as a product limit estimator based on the Kaplan-Meier method to account for censored events.
| Percentage of participants | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MTD+DL3B |
|---|---|---|---|---|---|---|---|---|---|
| Six-month Progression-free Survival Rate (6m-PFSR) | 66.7 (5.4 to 94.5) | 66.7 (19.5 to 90.4) | NA (NA to NA) | 30.0 (7.1 to 57.8) | 36.4 (11.2 to 62.7) | 27.3 (6.5 to 53.9) | 25.0 (3.7 to 55.8) | 36.2 (13.4 to 59.9) | 36.5 (17.0 to 56.3) |
OS was defined as the time from the date of first dose to the date of death due to any cause. Following the end of treatment visit, survival status was collected in all participants every month until 12 months (365 days) had elapsed from the last dose of investigational product.
| Months | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MTD+DL3B |
|---|---|---|---|---|---|---|---|---|---|
| Overall Survival (OS) | 9.8 (8.8 to 16.3) | 23.4 (5.6 to NA) | 3.3 (2.1 to 7.7) | 7.2 (4.0 to 15.3) | 9.9 (0.8 to 14.8) | 5.3 (2.4 to 11.7) | 7.2 (4.0 to NA) | 11.4 (4.5 to 14.9) | 12.1 (6.4 to 14.8) |
p16 is a tumor suppressor protein which plays an important role in cell cycle regulation. The analysis of biomarker p16 expression might aid in the identification of patient subpopulations most likely to benefit from treatment. The results from p16 expression testing by immunohistochemistry (IHC) was used for sensitivity analyses. (a) and (b) :p16 cutoff utilizing the optimal cut point identified by the ORC analysis for the OS (a) or PFS (b) and the p16 positive tumor cells.
| Participants | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MTD+DL3B |
|---|---|---|---|---|---|---|---|---|---|
| p16(a) | 1 | 2 | 0 | 5 | 7 | 6 | 3 | 10 | 15 |
| p16(b) | 1 | 1 | 0 | 4 | 6 | 4 | 1 | 9 | 13 |
Rb is a tumor suppressor protein that is dysfunctional in several major cancers. The results from Rb expression testing by IHC was used for sensitivity analyses.
| Percentage of positive cell | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MTD+DL3B |
|---|---|---|---|---|---|---|---|---|---|
| Retinoblastoma Protein (Rb) Percent Positive Cell (Nuclear Staining) | 88.3 ± 7.64 | 80.0 ± 29.79 | 68.8 ± 23.23 | 91.1 ± 10.24 | 90.5 ± 18.77 | 92.5 ± 8.25 | 82.2 ± 32.70 | 92.4 ± 19.10 | 91.7 ± 19.54 |
Rb is a tumor suppressor protein that is dysfunctional in several major cancers. The results from Rb expression testing by IHC was used for sensitivity analyses. The H-score is a method of assessing the extent of nuclear immunoreactivity, applicable to steroid receptors. The score is obtained by the formula: 3\*percentage of strongly staining nuclei + 2\*percentage of moderately staining nuclei + percentage of weakly staining nuclei, giving the range of 0 to 300
| Scores on a scale | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MTD+DL3B |
|---|---|---|---|---|---|---|---|---|---|
| Rb H-score Nuclear Staining | 158.3 ± 34.03 | 154.0 ± 65.9 | 108.8 ± 43.28 | 166.7 ± 32.88 | 176.0 ± 47.31 | 172.5 ± 32.17 | 145.6 ± 70.51 | 187.9 ± 52.37 | 185.4 ± 51.63 |
The palbociclib multiple dose maximum plasma concentration(Cmax) was observed directly from data.
| nanogram per milli liter (ng/mL) | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | Overall Participants With Dose Normalized to 125 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|
| Palbociclib Multiple Dose Maximum Plasma Concentration (Cmax) | NA ± NA | 90.68 ± 24 | 57.30 ± 56 | 98.79 ± 46 | 64.55 ± 23 | 48.05 ± 54 | 53.65 ± 25 | 70.14 ± 43 | 90.44 ± 39 |
The palbociclib multiple dose time for Cmax (Tmax) was observed directly from data.
| hour(hr) | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | Overall Participants With Dose Normalized to 125 mg/m^2. |
|---|---|---|---|---|---|---|---|---|---|
| Palbociclib Multiple Dose Time for Cmax (Tmax) | 4.93 (4.20 to 5.65) | 5.00 (4.00 to 7.92) | 3.90 (3.00 to 24.0) | 5.83 (4.05 to 25.0) | 4.50 (3.88 to 6.25) | 5.00 (1.83 to 7.17) | 6.01 (0 to 8.00) | 4.17 (0.600 to 7.98) | 5.05 (0 to 25.0) |
The palbociclib area under the plasma concentration-time curve for dosing interval τ (AUCτ) was observed directly from data.
| nanogram*hour per milli liter (ng.hr/mL) | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | Overall Participants With Dose Normalized to 125 mg/m^2. |
|---|---|---|---|---|---|---|---|---|---|
| Palbociclib Area Under the Plasma Concentration-time Curve for Dosing Interval τ (AUCτ) | NA ± NA | 1497 ± 18 | 897.4 ± 36 | 1867 ± 40 | 1169 ± 21 | 767.9 ± 42 | 967.7 ± 26 | 1251 ± 38 | 1569 ± 34 |
The palbociclib multiple dose trough plasma concentration (Ctrough) was observed directly from data.
| ng/mL | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | Overall Participants With Dose Normalized to 125 mg/m^2. |
|---|---|---|---|---|---|---|---|---|---|
| Palbociclib Multiple Dose Trough Plasma Concentration(Ctrough) | NA ± NA | 43.42 ± 34 | 26.84 ± 19 | 71.82 ± 42 | 41.92 ± 11 | 22.34 ± 37 | 30.66 ± 34 | 34.89 ± 34 | 48.51 ± 38 |
The palbociclib multiple dose apparent clearance (CL/F) was observed directly from data.
| liter per hour (L/hr) | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | Overall Participants With Dose Normalized to 125 mg/m^2. |
|---|---|---|---|---|---|---|---|---|---|
| Palbociclib Multiple Dose Apparent Clearance (CL/F) | NA ± NA | 66.67 ± 18 | 83.63 ± 36 | 64.52 ± 40 | 85.42 ± 21 | 97.67 ± 42 | 77.62 ± 26 | 79.95 ± 38 | 79.35 ± 34 |
The nab-P Cmax on Cycle 1 Day -1 and Day 13 were observed directly from data.
| ng/mL | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | Overall Participants With Dose Normalized to 125 mg/m^2. |
|---|---|---|---|---|---|---|---|---|---|
| Day -1 | 1208 ± 250 | 1595 ± 61 | 1869 ± 47 | 2733 ± 127 | 3396 ± 117 | 3271 ± 113 | 1851 ± 196 | 3054 ± 129 | 2827 ± 121 |
| Day 13 | NA ± NA | 1532 ± 146 | 2316 ± 56 | 1265 ± 219 | 3073 ± 57 | 2821 ± 93 | 1266 ± 167 | 3448 ± 73 | 2487 ± 111 |
The nab-P Tmax on Day -1 and Day 13 were observed directly from data.
| hr | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | Overall Participants With Dose Normalized to 125 mg/m^2. |
|---|---|---|---|---|---|---|---|---|---|
| Day -1 | 0.500 (0.500 to 1.00) | 1.00 (0.500 to 1.13) | 1.00 (0.517 to 1.00) | 0.567 (0.483 to 1.00) | 0.600 (0.483 to 1.00) | 0.500 (0.450 to 1.03) | 0.775 (0.500 to 1.00) | 0.500 (0.000 to 1.17) | 0.517 (0.000 to 1.17) |
| Day 13 | 0.592 (0.583 to 0.600) | 0.583 (0.500 to 1.20) | 0.500 (0.500 to 1.00) | 1.00 (0.500 to 1.05) | 0.517 (0.467 to 1.00) | 0.500 (0.450 to 1.17) | 0.575 (0.500 to 1.03) | 0.533 (0.467 to 1.50) | 0.542 (0.450 to 1.50) |
The nab-P area under the plasma concentration-time curve from time 0 to last quantifiable concentration (AUClast) on Day -1 and Day 13 were observed directly from data.
| ng.hr/mL | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | Overall Participants With Dose Normalized to 125 mg/m^2. |
|---|---|---|---|---|---|---|---|---|---|
| Day -1 | 2071 ± 127 | 3501 ± 48 | 3489 ± 33 | 4291 ± 70 | 4895 ± 54 | 4472 ± 59 | 2632 ± 146 | 3942 ± 60 | 4211 ± 70 |
| Day 13 | NA ± NA | 2592 ± 70 | 4096 ± 64 | 2894 ± 133 | 4095 ± 32 | 4183 ± 44 | 2071 ± 100 | 4269 ± 52 | 3812 ± 67 |
The nab-P area under the plasma concentration-time curve from time 0 extrapolated to infinite time (AUCinf) on Day -1 and Day 13 observed directly from data.
| ng.hr/mL | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | Overall Participants With Dose Normalized to 125 mg/m^2. |
|---|---|---|---|---|---|---|---|---|---|
| Day -1 | NA ± NA | 3851 ± 50 | 3780 ± 30 | 4157 ± 48 | 5387 ± 54 | 5132 ± 56 | 4116 ± 34 | 4760 ± 49 | 4977 ± 46 |
| Day 13 | NA ± NA | NA ± NA | 4590 ± 60 | 3349 ± 67 | 4493 ± 29 | 4482 ± 46 | 2206 ± 118 | 5135 ± 38 | 4447 ± 55 |
The nab-P t1/2 on Day -1 and Day 13 were observed directly from data.
| hr | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | Overall Participants With Dose Normalized to 125 mg/m^2. |
|---|---|---|---|---|---|---|---|---|---|
| Day -1 | 16.95 (16.6 to 17.3) | 11.10 (7.75 to 18.6) | 12.00 (10.9 to 16.6) | 15.25 (10.0 to 20.1) | 12.85 (9.41 to 16.1) | 16.10 (9.30 to 31.3) | 15.80 (9.31 to 20.4) | 14.45 (8.86 to 20.8) | 14.50 (7.75 to 31.3) |
| Day 13 | 15.20 (13.4 to 17.0) | 17.65 (13.0 to 22.3) | 18.60 (12.3 to 20.8) | 16.40 (15.7 to 19.3) | 17.10 (7.51 to 21.9) | 13.80 (9.82 to 18.8) | 14.35 (2.76 to 18.8) | 14.40 (9.26 to 24.3) | 15.20 (2.76 to 24.3) |
The nab-P clearance on Day -1 and Day 13 were observed directly from data.
| liter per hour (L/hr) | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | Overall Participants With Dose Normalized to 125 mg/m^2. |
|---|---|---|---|---|---|---|---|---|---|
| Day -1 | NA ± NA | 42.05 ± 56 | 60.94 ± 36 | 41.69 ± 51 | 37.77 ± 46 | 44.02 ± 51 | 42.39 ± 34 | 47.39 ± 48 | 43.63 ± 46 |
| Day 13 | NA ± NA | NA ± NA | 52.34 ± 65 | 50.14 ± 78 | 46.37 ± 33 | 47.89 ± 48 | 76.34 ± 131 | 44.92 ± 40 | 49.35 ± 57 |
The nab-P on Day -1 and Day 13 were observed directly from data.
| L | DL1 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | Overall Participants With Dose Normalized to 125 mg/m^2. |
|---|---|---|---|---|---|---|---|---|---|
| Day -1 | NA ± NA | 709.1 ± 44 | 1140 ± 44 | 891.3 ± 37 | 701.6 ± 46 | 943.3 ± 56 | 904.5 ± 39 | 950.8 ± 51 | 873.3 ± 46 |
| Day 13 | NA ± NA | NA ± NA | 1271 ± 106 | 1235 ± 69 | 1070 ± 71 | 927.2 ± 32 | 1220 ± 57 | 971.1 ± 52 | 1036 ± 52 |
Collected over From the signing of informed consent up to 56 days after the last administration of the investigational product, or 365 days from the first dose of investigational product, whichever is later.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DL1 Palbociclib 75mg / Nab-Paclitaxel 100mg/m^2 | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| DL2A Palbociclib 100mg / Nab-Paclitaxel 100mg/m^2 | 1/7 (14.3%) | 4/7 (57.1%) | 7/7 (100%) |
| DL2B Palbociclib 75mg / Nab-Paclitaxel 125mg/m^2 | 3/4 (75%) | 3/4 (75%) | 4/4 (100%) |
| DL3A Palbociclib 125mg / Nab-Paclitaxel 100mg/m^2 | 2/11 (18.2%) | 4/11 (36.4%) | 11/11 (100%) |
| DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | 3/11 (27.3%) | 6/11 (54.5%) | 10/11 (90.9%) |
| MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | 5/11 (45.5%) | 9/11 (81.8%) | 11/11 (100%) |
| MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | 2/9 (22.2%) | 2/9 (22.2%) | 9/9 (100%) |
| MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | 6/20 (30%) | 12/20 (60%) | 20/20 (100%) |
| MTD+DL3B | 7/27 (25.9%) | 15/27 (55.6%) | 27/27 (100%) |
| Event | DL1 Palbociclib 75mg / Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg / Nab-Paclitaxel 100mg/m^2 | DL2B Palbociclib 75mg / Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg / Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MTD+DL3B |
|---|---|---|---|---|---|---|---|---|---|
| Disease progressionGeneral disorders | 0/3 | 1/7 | 1/4 | 0/11 | 1/11 | 4/11 | 0/9 | 1/20 | 2/27 |
| Abdominal painGastrointestinal disorders | 1/3 | 0/7 | 0/4 | 0/11 | 0/11 | 1/11 | 0/9 | 2/20 | 2/27 |
| vomitingGastrointestinal disorders | 1/3 | 0/7 | 0/4 | 0/11 | 0/11 | 1/11 | 0/9 | 1/20 | 1/27 |
| Liver abscessInfections and infestations | 1/3 | 0/7 | 0/4 | 0/11 | 0/11 | 1/11 | 0/9 | 0/20 | 0/27 |
| EmpyemaInfections and infestations | 1/3 | 0/7 | 0/4 | 0/11 | 0/11 | 0/11 | 0/9 | 0/20 | 0/27 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/3 | 0/7 | 0/4 | 0/11 | 0/11 | 1/11 | 0/9 | 0/20 | 0/27 |
| CholangitisHepatobiliary disorders | 0/3 | 2/7 | 1/4 | 0/11 | 0/11 | 1/11 | 0/9 | 0/20 | 0/27 |
| PyrexiaGeneral disorders | 0/3 | 0/7 | 1/4 | 1/11 | 0/11 | 0/11 | 0/9 | 0/20 | 0/27 |
| Back painMusculoskeletal and connective tissue disorders | 0/3 | 0/7 | 1/4 | 0/11 | 0/11 | 0/11 | 0/9 | 0/20 | 0/27 |
| SeizureNervous system disorders | 0/3 | 0/7 | 1/4 | 0/11 | 0/11 | 0/11 | 0/9 | 0/20 | 0/27 |
| Event | DL1 Palbociclib 75mg / Nab-Paclitaxel 100mg/m^2 | DL2A Palbociclib 100mg / Nab-Paclitaxel 100mg/m^2 | DL2B Palbociclib 75mg / Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg / Nab-Paclitaxel 100mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MTD+DL3B |
|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/3 | 6/7 | 1/4 | 2/11 | 4/11 | 5/11 | 2/9 | 9/20 | 12/27 |
| AlopeciaSkin and subcutaneous tissue disorders | 1/3 | 6/7 | 1/4 | 3/11 | 4/11 | 6/11 | 3/9 | 6/20 | 9/27 |
| NeutropeniaBlood and lymphatic system disorders | 2/3 | 5/7 | 1/4 | 9/11 | 7/11 | 5/11 | 6/9 | 16/20 | 20/27 |
| Early satietyGeneral disorders | 2/3 | 1/7 | 0/4 | 0/11 | 0/11 | 0/11 | 0/9 | 0/20 | 0/27 |
| PyrexiaGeneral disorders | 2/3 | 4/7 | 1/4 | 0/11 | 1/11 | 2/11 | 1/9 | 5/20 | 6/27 |
| DehydrationMetabolism and nutrition disorders | 2/3 | 0/7 | 1/4 | 0/11 | 2/11 | 1/11 | 0/9 | 3/20 | 5/27 |
| DysgeusiaNervous system disorders | 2/3 | 3/7 | 1/4 | 0/11 | 1/11 | 1/11 | 1/9 | 0/20 | 1/27 |
| Decreased appetiteMetabolism and nutrition disorders | 1/3 | 2/7 | 1/4 | 1/11 | 4/11 | 7/11 | 5/9 | 3/20 | 7/27 |
| Abdominal painGastrointestinal disorders | 1/3 | 3/7 | 0/4 | 1/11 | 2/11 | 4/11 | 5/9 | 4/20 | 5/27 |
| AnaemiaBlood and lymphatic system disorders | 1/3 | 2/7 | 2/4 | 5/11 | 3/11 | 6/11 | 1/9 | 9/20 | 11/27 |
The baseline analysis population included all participants enrolled in the study.
| Age, Customized(Participants) | DL1 Palbociclib 75 mg/Nab-Paclitaxel 100 mg /m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100mg/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100 mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | Total |
|---|---|---|---|---|---|---|---|---|---|
| <18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 18-44 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 2 | 4 |
| 45-64 | 2 | 5 | 3 | 5 | 6 | 7 | 8 | 9 | 45 |
| 65-75 | 1 | 1 | 1 | 5 | 5 | 4 | 1 | 9 | 27 |
| >75 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | DL1 Palbociclib 75 mg/Nab-Paclitaxel 100 mg /m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100mg/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100 mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 5 | 1 | 6 | 5 | 3 | 6 | 6 | 34 |
| Male | 1 | 2 | 3 | 5 | 6 | 8 | 3 | 14 | 42 |
| Race/Ethnicity, Customized(Participants) | DL1 Palbociclib 75 mg/Nab-Paclitaxel 100 mg /m^2 | DL2A Palbociclib 100mg/Nab-Paclitaxel 100mg/m^2 | DL2B Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | DL3A Palbociclib 125mg/Nab-Paclitaxel 100 mg/m^2 | DL3B Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | MDR1 Palbociclib 75mg/Nab-Paclitaxel 125mg/m^2 | MDR2 Palbociclib 75mg/Nab-Paclitaxel 100mg/m^2 | MTD Palbociclib 100mg/Nab-Paclitaxel 125mg/m^2 | Total |
|---|---|---|---|---|---|---|---|---|---|
| White | 3 | 6 | 4 | 11 | 11 | 11 | 8 | 20 | 74 |
| Asian | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Nov 2015 to primary completion in Oct 2018, 34 months.
Results were first posted in Apr 2021, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Palbociclib · Albumin-Bound Paclitaxel